$CTIC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CTI BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in CTI BIOPHARMA CORP. Get notifications about new insider transactions in CTI BIOPHARMA CORP for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 13 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 1,000 | 2,400 | 419,668 | 420.7 K to 419.7 K (-0.24 %) |
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 800 | 1,916 | 420,668 | 421.5 K to 420.7 K (-0.19 %) |
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.39 | 2,400 | 5,736 | 421,468 | 423.9 K to 421.5 K (-0.57 %) |
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.39 | 2,500 | 5,963 | 423,868 | 426.4 K to 423.9 K (-0.59 %) |
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.38 | 2,700 | 6,429 | 426,368 | 429.1 K to 426.4 K (-0.63 %) |
Nov 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.37 | 900 | 2,133 | 429,068 | 430 K to 429.1 K (-0.21 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.41 | 1,000 | 2,410 | 429,968 | 431 K to 430 K (-0.23 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.41 | 100 | 241 | 430,968 | 431.1 K to 431 K (-0.02 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 2,138 | 5,131 | 431,068 | 433.2 K to 431.1 K (-0.49 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.40 | 4,200 | 10,059 | 433,206 | 437.4 K to 433.2 K (-0.96 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.39 | 3,062 | 7,318 | 437,406 | 440.5 K to 437.4 K (-0.70 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.39 | 800 | 1,908 | 440,468 | 441.3 K to 440.5 K (-0.18 %) |
Oct 08 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.38 | 700 | 1,666 | 441,268 | 442 K to 441.3 K (-0.16 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO JAMES A | President and CEO | Sell | S | 2.53 | 307,068 | 776,575 | 1,950,726 | 2.3 M to 2 M (-13.60 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.58 | 1,600 | 4,128 | 441,968 | 443.6 K to 442 K (-0.36 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.57 | 600 | 1,542 | 443,568 | 444.2 K to 443.6 K (-0.14 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.56 | 9,250 | 23,680 | 444,168 | 453.4 K to 444.2 K (-2.04 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.55 | 14,118 | 36,001 | 453,418 | 467.5 K to 453.4 K (-3.02 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.54 | 3,300 | 8,382 | 467,536 | 470.8 K to 467.5 K (-0.70 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.53 | 2,600 | 6,578 | 470,836 | 473.4 K to 470.8 K (-0.55 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.52 | 722 | 1,819 | 473,436 | 474.2 K to 473.4 K (-0.15 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.51 | 15,728 | 39,477 | 474,158 | 489.9 K to 474.2 K (-3.21 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.50 | 3,900 | 9,750 | 489,886 | 493.8 K to 489.9 K (-0.79 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.63 | 2,200 | 5,786 | 493,786 | 496 K to 493.8 K (-0.44 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.62 | 2,635 | 6,904 | 495,986 | 498.6 K to 496 K (-0.53 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.61 | 1,408 | 3,675 | 498,621 | 500 K to 498.6 K (-0.28 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.60 | 3,901 | 10,143 | 500,029 | 503.9 K to 500 K (-0.77 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.59 | 2,793 | 7,234 | 503,930 | 506.7 K to 503.9 K (-0.55 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.58 | 27,400 | 70,692 | 506,723 | 534.1 K to 506.7 K (-5.13 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.57 | 3,000 | 7,710 | 534,123 | 537.1 K to 534.1 K (-0.56 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.56 | 981 | 2,511 | 537,123 | 538.1 K to 537.1 K (-0.18 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.55 | 300 | 765 | 538,104 | 538.4 K to 538.1 K (-0.06 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.54 | 300 | 762 | 538,404 | 538.7 K to 538.4 K (-0.06 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.53 | 3,500 | 8,855 | 538,704 | 542.2 K to 538.7 K (-0.65 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.52 | 799 | 2,013 | 542,204 | 543 K to 542.2 K (-0.15 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.51 | 1,500 | 3,765 | 543,003 | 544.5 K to 543 K (-0.28 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.50 | 600 | 1,500 | 544,503 | 545.1 K to 544.5 K (-0.11 %) |
Sep 24 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 500 | 1,245 | 545,103 | 545.6 K to 545.1 K (-0.09 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.68 | 5,600 | 15,008 | 647,897 | 653.5 K to 647.9 K (-0.86 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.63 | 100 | 263 | 653,497 | 653.6 K to 653.5 K (-0.02 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.62 | 9,660 | 25,309 | 653,597 | 663.3 K to 653.6 K (-1.46 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.61 | 2,300 | 6,003 | 663,257 | 665.6 K to 663.3 K (-0.35 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.60 | 14,300 | 37,180 | 665,557 | 679.9 K to 665.6 K (-2.10 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.60 | 3,700 | 9,602 | 679,857 | 683.6 K to 679.9 K (-0.54 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.59 | 37,200 | 96,348 | 683,557 | 720.8 K to 683.6 K (-5.16 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.59 | 12,200 | 31,537 | 720,757 | 733 K to 720.8 K (-1.66 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.58 | 200 | 517 | 732,957 | 733.2 K to 733 K (-0.03 %) |
Sep 19 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.58 | 59,740 | 154,129 | 733,157 | 792.9 K to 733.2 K (-7.53 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 1,630 | 4,059 | 545,603 | 547.2 K to 545.6 K (-0.30 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 100 | 249 | 547,233 | 547.3 K to 547.2 K (-0.02 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 2,200 | 5,467 | 547,333 | 549.5 K to 547.3 K (-0.40 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.48 | 8,901 | 22,074 | 549,533 | 558.4 K to 549.5 K (-1.59 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.48 | 5,500 | 13,613 | 558,434 | 563.9 K to 558.4 K (-0.98 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.47 | 8,870 | 21,909 | 563,934 | 572.8 K to 563.9 K (-1.55 %) |
Sep 05 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.47 | 100 | 247 | 572,804 | 572.9 K to 572.8 K (-0.02 %) |
Aug 15 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO JAMES A | President and CEO | Sell | S | 2.54 | 40,000 | 101,720 | 2,257,794 | 2.3 M to 2.3 M (-1.74 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.53 | 300 | 759 | 572,904 | 573.2 K to 572.9 K (-0.05 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.52 | 300 | 756 | 573,204 | 573.5 K to 573.2 K (-0.05 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.52 | 100 | 252 | 573,504 | 573.6 K to 573.5 K (-0.02 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.51 | 1,500 | 3,765 | 573,604 | 575.1 K to 573.6 K (-0.26 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.51 | 100 | 251 | 575,104 | 575.2 K to 575.1 K (-0.02 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.50 | 800 | 2,000 | 575,204 | 576 K to 575.2 K (-0.14 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.50 | 1,000 | 2,495 | 576,004 | 577 K to 576 K (-0.17 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 600 | 1,494 | 577,004 | 577.6 K to 577 K (-0.10 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.49 | 400 | 994 | 577,604 | 578 K to 577.6 K (-0.07 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.48 | 200 | 496 | 578,004 | 578.2 K to 578 K (-0.03 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.47 | 800 | 1,976 | 578,204 | 579 K to 578.2 K (-0.14 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.47 | 600 | 1,479 | 579,004 | 579.6 K to 579 K (-0.10 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.46 | 2,000 | 4,920 | 579,604 | 581.6 K to 579.6 K (-0.34 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.46 | 1,100 | 2,701 | 581,604 | 582.7 K to 581.6 K (-0.19 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.45 | 1,300 | 3,185 | 582,704 | 584 K to 582.7 K (-0.22 %) |
Aug 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.45 | 900 | 2,201 | 584,004 | 584.9 K to 584 K (-0.15 %) |
Jul 11 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.73 | 10,000 | 27,300 | 792,897 | 802.9 K to 792.9 K (-1.25 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.96 | 600 | 1,776 | 584,904 | 585.5 K to 584.9 K (-0.10 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.96 | 200 | 591 | 585,504 | 585.7 K to 585.5 K (-0.03 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.94 | 200 | 588 | 585,704 | 585.9 K to 585.7 K (-0.03 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.94 | 600 | 1,761 | 585,904 | 586.5 K to 585.9 K (-0.10 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.93 | 1,700 | 4,981 | 586,504 | 588.2 K to 586.5 K (-0.29 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.93 | 900 | 2,633 | 588,204 | 589.1 K to 588.2 K (-0.15 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.92 | 1,700 | 4,964 | 589,104 | 590.8 K to 589.1 K (-0.29 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.90 | 600 | 1,740 | 590,804 | 591.4 K to 590.8 K (-0.10 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.88 | 600 | 1,728 | 591,404 | 592 K to 591.4 K (-0.10 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.87 | 200 | 573 | 592,004 | 592.2 K to 592 K (-0.03 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.86 | 600 | 1,716 | 592,204 | 592.8 K to 592.2 K (-0.10 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.86 | 500 | 1,428 | 592,804 | 593.3 K to 592.8 K (-0.08 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.85 | 1,000 | 2,850 | 593,304 | 594.3 K to 593.3 K (-0.17 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.85 | 900 | 2,561 | 594,304 | 595.2 K to 594.3 K (-0.15 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.84 | 800 | 2,272 | 595,204 | 596 K to 595.2 K (-0.13 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.84 | 100 | 284 | 596,004 | 596.1 K to 596 K (-0.02 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.82 | 500 | 1,410 | 596,104 | 596.6 K to 596.1 K (-0.08 %) |
Jul 09 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.82 | 300 | 845 | 596,604 | 596.9 K to 596.6 K (-0.05 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 3.00 | 1,800 | 5,400 | 802,897 | 804.7 K to 802.9 K (-0.22 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.99 | 1,100 | 3,289 | 804,697 | 805.8 K to 804.7 K (-0.14 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.98 | 1,100 | 3,278 | 805,797 | 806.9 K to 805.8 K (-0.14 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.97 | 600 | 1,782 | 806,897 | 807.5 K to 806.9 K (-0.07 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.97 | 200 | 593 | 807,497 | 807.7 K to 807.5 K (-0.02 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.96 | 4,200 | 12,432 | 807,697 | 811.9 K to 807.7 K (-0.52 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.95 | 100 | 295 | 811,897 | 812 K to 811.9 K (-0.01 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.95 | 900 | 2,655 | 811,997 | 812.9 K to 812 K (-0.11 %) |
Jun 27 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO JAMES A | President and CEO | Sell | S | 2.84 | 50,000 | 142,000 | 2,297,794 | 2.3 M to 2.3 M (-2.13 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO JAMES A | President and CEO | Sell | S | 2.99 | 55,000 | 164,450 | 2,347,794 | 2.4 M to 2.3 M (-2.29 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.07 | 200 | 614 | 596,904 | 597.1 K to 596.9 K (-0.03 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.06 | 500 | 1,530 | 597,104 | 597.6 K to 597.1 K (-0.08 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.05 | 700 | 2,135 | 597,604 | 598.3 K to 597.6 K (-0.12 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.05 | 800 | 2,436 | 598,304 | 599.1 K to 598.3 K (-0.13 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.04 | 1,189 | 3,615 | 599,104 | 600.3 K to 599.1 K (-0.20 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.04 | 100 | 304 | 600,293 | 600.4 K to 600.3 K (-0.02 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.03 | 700 | 2,121 | 600,393 | 601.1 K to 600.4 K (-0.12 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.03 | 300 | 908 | 601,093 | 601.4 K to 601.1 K (-0.05 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.02 | 2,300 | 6,946 | 601,393 | 603.7 K to 601.4 K (-0.38 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.02 | 1,200 | 3,618 | 603,693 | 604.9 K to 603.7 K (-0.20 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.01 | 2,100 | 6,321 | 604,893 | 607 K to 604.9 K (-0.35 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.01 | 900 | 2,705 | 606,993 | 607.9 K to 607 K (-0.15 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 3.00 | 11 | 33 | 607,893 | 607.9 K to 607.9 K (0.00 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.98 | 300 | 893 | 607,904 | 608.2 K to 607.9 K (-0.05 %) |
Jun 06 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.97 | 700 | 2,079 | 608,204 | 608.9 K to 608.2 K (-0.11 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Grant | A | 0.00 | 34,844 | 0 | 436,014 | 401.2 K to 436 K (+8.69 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Grant | A | 0.00 | 34,844 | 0 | 571,506 | 536.7 K to 571.5 K (+6.49 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Grant | A | 0.00 | 43,555 | 0 | 492,174 | 448.6 K to 492.2 K (+9.71 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | MUNDINGER MARY ONEIL | Director | Grant | A | 0.00 | 34,844 | 0 | 401,179 | 366.3 K to 401.2 K (+9.51 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Grant | A | 0.00 | 34,844 | 0 | 544,109 | 509.3 K to 544.1 K (+6.84 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | Ignagni Karen | Director | Grant | A | 0.00 | 34,844 | 0 | 66,192 | 31.3 K to 66.2 K (+111.15 %) |
May 23 2014 | CTIC | CTI BIOPHARMA CORP | BAUER JOHN H | Director | Grant | A | 0.00 | 34,844 | 0 | 599,011 | 564.2 K to 599 K (+6.18 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.98 | 38 | 113 | 608,904 | 608.9 K to 608.9 K (-0.01 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.98 | 700 | 2,083 | 608,942 | 609.6 K to 608.9 K (-0.11 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.97 | 3,517 | 10,445 | 609,642 | 613.2 K to 609.6 K (-0.57 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.97 | 100 | 297 | 613,159 | 613.3 K to 613.2 K (-0.02 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.97 | 2,400 | 7,116 | 613,259 | 615.7 K to 613.3 K (-0.39 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.96 | 1,300 | 3,848 | 615,659 | 617 K to 615.7 K (-0.21 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.96 | 400 | 1,182 | 616,959 | 617.4 K to 617 K (-0.06 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.95 | 745 | 2,198 | 617,359 | 618.1 K to 617.4 K (-0.12 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.94 | 1,100 | 3,234 | 618,104 | 619.2 K to 618.1 K (-0.18 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.94 | 300 | 881 | 619,204 | 619.5 K to 619.2 K (-0.05 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.93 | 1,100 | 3,223 | 619,504 | 620.6 K to 619.5 K (-0.18 %) |
May 07 2014 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Corporate Deve ... | Sell | S | 2.93 | 300 | 878 | 620,604 | 620.9 K to 620.6 K (-0.05 %) |
May 02 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.92 | 2,800 | 8,162 | 812,897 | 815.7 K to 812.9 K (-0.34 %) |
May 02 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.91 | 2,200 | 6,402 | 815,697 | 817.9 K to 815.7 K (-0.27 %) |
May 02 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.91 | 800 | 2,324 | 817,897 | 818.7 K to 817.9 K (-0.10 %) |
May 02 2014 | CTIC | CTI BIOPHARMA CORP | BIANCO LOUIS A | EVP, Finance & Admi ... | Sell | S | 2.90 | 4,200 | 12,180 | 818,697 | 822.9 K to 818.7 K (-0.51 %) |
Mar 28 2014 | CTIC | CTI BIOPHARMA CORP | GREGORIAN VARTAN | Director | Sell | S | 3.42 | 20,000 | 68,400 | 468,937 | 488.9 K to 468.9 K (-4.09 %) |
Mar 28 2014 | CTIC | CTI BIOPHARMA CORP | GREGORIAN VARTAN | Director | Sell | S | 3.41 | 55,000 | 187,550 | 488,937 | 543.9 K to 488.9 K (-10.11 %) |
Mar 28 2014 | CTIC | CTI BIOPHARMA CORP | GREGORIAN VARTAN | Director | Sell | S | 3.41 | 5,900 | 20,090 | 543,937 | 549.8 K to 543.9 K (-1.07 %) |
Mar 28 2014 | CTIC | CTI BIOPHARMA CORP | GREGORIAN VARTAN | Director | Sell | S | 3.40 | 200 | 681 | 549,837 | 550 K to 549.8 K (-0.04 %) |
Mar 28 2014 | CTIC | CTI BIOPHARMA CORP | GREGORIAN VARTAN | Director | Sell | S | 3.40 | 900 | 3,060 | 550,037 | 550.9 K to 550 K (-0.16 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.59 | 100 | 359 | 448,619 | 448.7 K to 448.6 K (-0.02 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.59 | 1,301 | 4,664 | 448,719 | 450 K to 448.7 K (-0.29 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.58 | 1,599 | 5,724 | 450,020 | 451.6 K to 450 K (-0.35 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.58 | 21,900 | 78,293 | 451,619 | 473.5 K to 451.6 K (-4.62 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.57 | 2,900 | 10,356 | 473,519 | 476.4 K to 473.5 K (-0.61 %) |
Mar 26 2014 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Sell | S | 3.57 | 20,500 | 73,185 | 476,419 | 496.9 K to 476.4 K (-4.13 %) |